Schapira A H
Lancet. 2000 Apr 15;355(9212):1332-3. doi: 10.1016/S0140-6736(00)02118-8.
Increased sedation, somnolence, and sleep episodes seem to occur with several, if not all, dopamine agonists and dopaminergic treatment. Patients at risk of sleep episodes can be identified by well-chosen questions, and could be managed by appropriate measures including dose reduction.
增加的镇静作用、嗜睡和睡眠发作似乎在几种(如果不是所有的话)多巴胺激动剂和多巴胺能治疗中都会出现。有睡眠发作风险的患者可以通过精心挑选的问题来识别,并可以通过包括减少剂量在内的适当措施来管理。